FDA approves Global Blood Therapeutics' sickle cell pill

Global Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the first treatment targeting the root cause of the condition.

CAR-TCR Summit Europe

Engineering A Cancer-Free World

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...

bluebird presents long-term data from CALD gene therapy

bluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy (CALD), showing that it continues to work in the long-te

bluebird offers instalment payments for Zynteglo gene therap...

bluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with an outcomes-based payment scheme to try to persuade healthcare systems to